Janssen Search
Search results
Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program
Oct 03, 2023 United States Vaccine candidate is being evaluated in Phase 3 study for the prevention of invasive E. coli disease (IED) which affects nearly 10 million adults annually 1 TITUSVILLE, N.J., October 3, 2023 – Janssen Pharmaceuticals, Inc. ...
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes
May 29, 2024 Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024 Approximately 60 ...
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Apr 06, 2024 United States Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 ...
Opening Vaccines Launch Facility
Article Type: Other About the Symposium The speakers include: Bruno Bruins- Minister for Medical Care and Sport of the Netherlands, Pierre Meulien of the EU’s Innovative Medicines Initiative (IMI), Jayasree K. Iyer of the Access to Vaccines Index (ATVI) ...
ASCO GU 2021
Thank you for visiting the Janssen Oncology newsroom to learn more about our research that will be presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium (ASCO GU). Janssen Oncology has 12 company-sponsored ...
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
May 02, 2023 United States Investigational CD20-targeted CAR-Ts Enhance Janssen’s B-cell Malignancy Portfolio Agreement Deepens Janssen’s Leadership in Oncology and Hematology, and Accelerates Commitment to Delivering Transformational Cell Therapies ...
Frank de Wolf, M.D., PH.D.
As Global Head of the Janssen Prevention Center, Frank de Wolf is responsible for driving research to develop new concepts for disease prevention that will extend the healthy life span. He was appointed to this position in March 2017. Frank has been Head ...
Sample Article
AArtwork title, Artist name Mar 11, 2015 Excepteur sint occaecat cupidatat non Cupidatat nesciunt neque porrosed quia non numquam eius velit Sed quia non numquam eius m Excepteur sint occaecat cupidatat non Excepteur sint occaecat cupidatat non Cupidatat ...
Working with Global Health Authorities
Article Type: Oncology Working with Global Health Authorities: Many Conversations, One Common Goal The ability to get new therapies to patients can be delayed by months or even years if a company is not able to navigate today’s complex regulatory ...
An Update on Our Vaccine Candidate to Prevent COVID-19
An Update on Our Vaccine Candidate to Prevent COVID-19 On July 21, I was pleased to represent Johnson & Johnson at a hearing before the Oversight and Investigations Subcommittee of the U.S. House Energy & Commerce Committee, to update the ...